Charles River Laboratories Raises 2026 Outlook for Revenue Growth and EPS
The company raised its 2026 outlook for organic revenue growth and earnings per share. It now expects revenue to decline 1.5% to 2.0%.
WASHINGTON (dpa-AFX) - Charles River Laboratories International, Inc. (CRL), a provider of drug discovery and development services, Wednesday raised its 2026 outlook for organic revenue growth and earnings per share.The company now expects revenue to decline 1.5% to 2.0% in 2026, compared with its…